Drug Profile
Research programme: DNA vaccines - Admedus Immunotherapies
Alternative Names: EBV vaccine - Admedus Immunotherapies; Epstein Barr Virus vaccine - Admedus ImmunotherapiesLatest Information Update: 28 Feb 2020
Price :
$50
*
At a glance
- Originator University of Queensland
- Developer Admedus Immunotherapies
- Class Cancer vaccines; DNA vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Epstein-Barr virus infections; Lymphoma
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for research development in Epstein-Barr-virus-infections in Australia (Parenteral, Injection)
- 28 Feb 2020 No recent reports of development identified for research development in Lymphoma(Prevention) in Australia (Parenteral, Injection)
- 16 Feb 2018 Admedus Vaccines is now called Admedus Immunotherapies